Von Willebrand Disease (VWD) - Market Insights, Epidemiology and Market Forecast-2027

  • ID: 4564660
  • Drug Pipelines
  • 103 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 4

FEATURED COMPANIES

  • CSL- Behring
  • Ferring Pharmaceuticals
  • Grifols Biological Inc
  • LFB
  • Octa Pharma
  • Shire
  • MORE
‘Von Willebrand Disease (VWD) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of VWD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Von Willebrand Disease (VWD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Von Willebrand Disease (VWD) - Disease Understanding and Treatment Algorithm

The Von Willebrand Disease (VWD) market report gives the thorough understanding of the Von Willebrand Disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Von Willebrand Disease in the US, EU5, and Japan.

Von Willebrand Disease Epidemiology

The Von Willebrand Disease (VWD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, sex- specific diagnosed prevalent cases, type specific diagnosed prevalent cases and age specific diagnosed prevalent cases) scenario of Von Willebrand Disease (VWD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to this research, the total number of diagnosed prevalent population of Von Willebrand Disease (VWD) was found to be 35,396, in the year 2016.

Von Willebrand Disease Drug Chapters

This segment of the Von Willebrand Disease report encloses the detailed analysis of marketed drugs and drugs which are in the registration/filing phase. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, there are broadly three therapeutic classes of drugs contributing towards the market size of VWD - Replacement Therapy, Non-Replacement Therapy and Adjunct/Supportive Therapy. The approved (and their generic versions) as well as off-label products that are being used for the treatment of Von Willebrand Disease, belong to either of these therapeutic classes only. Detailed chapter for marketed therapies along with their regulatory details like Vonvendi (also known as BAX 111) (Shire), Wilfacin (LFB), Humate-P (CSL-Behring), Alphanate (Grifols Biological Inc), Immunate (Shire) and Voncento (CSL-Behring) have been covered in the report.

Von Willebrand Disease Market Outlook

The Von Willebrand Disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of market trend of each marketed drug and their upcoming regulaotry filings for marketing approvals by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Von Willebrand Disease in 7MM was found to be USD 379.67 million in 2016.

Von Willebrand Disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Von Willebrand Disease Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Von Willebrand Disease Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Von Willebrand Disease Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Marketed Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits:
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Von Willebrand Disease market
  • Organize sales and marketing efforts by identifying the best opportunities for Von Willebrand Disease market
  • To understand the future market competition in the Von Willebrand Disease market.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • CSL- Behring
  • Ferring Pharmaceuticals
  • Grifols Biological Inc
  • LFB
  • Octa Pharma
  • Shire
  • MORE
1. Key Insights

2. Von Willebrand Disease (vWD): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of vWD in 2016
2.2. Total Market Share (%) Distribution of vWD in 2027

3. Disease Background and Overview: von Willebrand Disease (vWD)
3.1. Introduction
3.2. Classification
3.3. Clinical Manifestations
3.4. Pathophysiology
3.5. Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings

5. 7MM Total Diagnosed Prevalent Patient Population of von Willebrand Disease

6. Country Wise-Epidemiology of von Willebrand Disease
6.1. United States
6.1.1. Total Diagnosed Prevalent Population of von Willebrand Disease in the US
6.1.2. Sex-Specific Diagnosed Prevalent Population of von Willebrand Disease in the US
6.1.3. Type Specific Diagnosed Prevalent Population of Von Willebrand Disease in the US
6.1.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in the US
6.2. EU5 Countries
6.3. Germany
6.3.1. Total Diagnosed Prevalent Population of von Willebrand Disease in Germany
6.3.2. Sex-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany
6.3.3. Type Specific Diagnosed Prevalence of von Willebrand Disease in Germany
6.3.4. Age Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany
6.4. France
6.4.1. Total Diagnosed Prevalent Population of Von Willebrand Disease in France
6.4.2. Sex-Specific Diagnosed Prevalent Population of von Willebrand Disease in France
6.4.3. Type Specific Diagnosed Prevalence of Von Willebrand Disease in France
6.4.4. Age Specific Diagnosed Prevalent Population of Von Willebrand Disease in France
6.5. Italy
6.5.1. Total Diagnosed Prevalent Population of von Willebrand Disease in Italy
6.5.2. Sex-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Italy
6.5.3. Type Specific Diagnosed Prevalence of von Willebrand Disease in Italy
6.5.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in Italy
6.6. Spain
6.6.1. Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain
6.6.2. Sex-Specific Diagnosed Prevalent Population of von Willebrand Disease in Spain
6.6.3. Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain
6.6.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in Spain
6.7. United Kingdom
6.7.1. Total Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom
6.7.2. Sex-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom
6.7.3. Type Specific Diagnosed Prevalence of Von Willebrand Disease in the United Kingdom
6.7.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in United Kingdom
6.8. Japan
6.8.1. Total Diagnosed Prevalent Population of von Willebrand Disease in Japan
6.8.2. Sex-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Japan
6.8.3. Type Specific Diagnosed Prevalence of Von Willebrand Disease in Japan
6.8.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in Japan

7. Treatment Algorithm, Current Treatment, and Medical Practices

8. Unmet Needs
8.1. Marketed Drugs
8.2. VONVENDI: Shire
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Clinical Development
8.2.5. Advantages & Disadvantages
8.2.6. Safety and Efficacy
8.2.7. Product Profile
8.3. Voncento : CSL- Behring
8.3.1. Drug Description
8.3.2. Mechanism of Action
8.3.3. Regulatory Milestones
8.3.4. Advantages & Disadvantages
8.3.5. Safety and Efficacy
8.3.6. Product Profile
8.4. Humate P: CSL Behring
8.4.1. Drug Description
8.4.2. Mechanism of Action
8.4.3. Regulatory Milestones
8.4.4. Advantages & Disadvantages
8.4.5. Safety and Efficacy
8.4.6. Product Profile
8.5. WILATE : Octa Pharma
8.5.1. Drug Description
8.5.2. Mechanism of Action
8.5.3. Regulatory Milestones
8.5.4. Advantages & Disadvantages
8.5.5. Safety and Efficacy
8.5.6. Product Profile
8.6. Wilfactin: LFB
8.6.1. Drug Description
8.6.2. Mechanism of Action
8.6.3. Regulatory Milestones
8.6.4. Advantages & Disadvantages
8.6.5. Product Profile
8.7. Desmopressin: Ferring Pharmaceuticals
8.7.1. Drug Description
8.7.2. Mechanism of Action
8.7.3. Regulatory Milestones
8.7.4. Advantages & Disadvantages
8.7.5. Product Profile
8.8. ALPHANATE: Grifols Biological Inc
8.8.1. Drug Description
8.8.2. Mechanism of Action
8.8.3. Regulatory Milestones
8.8.4. Advantages & Disadvantages
8.8.5. Safety and Efficacy
8.8.6. Product Profile
8.9. Immunate: Shire
8.9.1. Drug Description
8.9.2. Mechanism of Action
8.9.3. Advantages & Disadvantages
8.9.4. Safety and Efficacy
8.9.5. Product Profile
8.10. Fanhdi: Grifols Biological Inc
8.10.1. Drug Description
8.10.2. Mechanism of Action
8.10.3. Regulatory Milestones
8.10.4. Advantages & Disadvantages
8.10.5. Safety and Efficacy
8.10.6. Product Profile

9. Von Willebrand Disease: 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of Von Willebrand Disease in 7MM

10. The United States Market Outlook
10.1. United States Market Size
10.1.1. Total Market size of Von Willebrand Disease
10.1.2. Market Size by Therapies

11. EU-5 Countries: Market Outlook
11.1. Germany
11.1.1. Total Market size of von Willebrand Disease in Germany
11.1.2. Market Size by Therapies
11.2. France
11.2.1. Total Market size of Von Willebrand Disease
11.2.2. Market Size by Therapies
11.3. Italy
11.3.1. Total Market size of Von Willebrand Disease
11.3.2. Market Size by Therapies
11.4. Spain
11.4.1. Total Market size of von Willebrand Disease
11.4.2. Market Size by Therapies
11.5. United Kingdom
11.5.1. Total Market size of Von Willebrand Disease
11.5.2. Market Size by Therapies
11.6. Japan: Market Outlook
11.6.1. Total Market size of von Willebrand Disease

12. Market Drivers

13. Market Barriers

14. Appendix
14.1. Report Methodology

15. Capabilities

16. Disclaimer

17. About the Publisher

List of Tables
Table 1: Classification of von Willebrand disease
Table 2: Sub-Classification of von Willebrand disease Type 2A
Table 3: Total Diagnosed Prevalent Population of Von Willebrand Disease in the 7MM (2016-2027)
Table 4: Total Diagnosed Prevalent Population of Von Willebrand Disease in the United States (2016-2027)
Table 5: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2016-2027)
Table 6: Type Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2016-2027)
Table 7: Age Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2016-2027)
Table 8: Total Diagnosed Prevalent Population of Von Willebrand Disease in Germany (2016-2027)
Table 9: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2016-2027)
Table 10: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2016-2027)
Table 11: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2016-2027)
Table 12: Total Diagnosed Prevalent Population of Von Willebrand Disease in France (2016-2027)
Table 13: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in France (2016-2027)
Table 14: Type Specific Diagnosed Prevalence of Von Willebrand Disease in France (2016-2027)
Table 15: Age Specific Diagnosed Prevalence of Von Willebrand Disease in France (2016-2027)
Table 16: Total Diagnosed Prevalent Population of Von Willebrand Disease in Italy (2016-2027)
Table 17: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2016-2027)
Table 18: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2016-2027)
Table 19: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2016-2027)
Table 20: Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain (2016-2027)
Table 21: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2016-2027)
Table 22: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2016-2027)
Table 23: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2016-2027)
Table 24: Total Diagnosed Prevalent Population of Von Willebrand Disease in the UK (2016-2027)
Table 25: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2016-2027)
Table 26: Type Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2016-2027)
Table 27: Age Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2016-2027)
Table 28: Total Diagnosed Prevalent Population of Von Willebrand Disease in Japan (2016-2027)
Table 29: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2016-2027)
Table 30: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2016-2027)
Table 31: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2016-2027)
Table 32: Treatment of von Willebrand Disease
Table 33: Indications for Replacement Therapy in VWD
Table 34: 7 Major Market Size of Von Willebrand Disease in USD Million (2016-2027)
Table 35: United States Market Size of Von Willebrand Disease in USD Million (2016-2027)
Table 36: Market size of Von Willebrand Disease by therapies in United States, in USD Million (2016-2027)
Table 37: Market Size of Von Willebrand Disease in Germany, in USD Million (2016-2027)
Table 38: Market Size of Von Willebrand Disease by therapies in Germany, in USD Million (2016-2027)
Table 39: Market Size of Von Willebrand Disease in France, in USD Million (2016-2027)
Table 40:Market Size of Von Willebrand Disease by therapies in France, in USD Million (2016-2027)
Table 41: Market Size of Von Willebrand Disease in Italy, in USD Million (2016-2027)
Table 42:Market Size of Von Willebrand Disease by therapies in Italy, in USD Million (2016-2027)
Table 43: Market Size of Von Willebrand Disease in Spain, in USD Million (2016-2027)
Table 44:Market Size of Von Willebrand Disease by therapies in Spain, in USD Million (2016-2027)
Table 45: Market Size of Von Willebrand Disease in the UK, in USD Million (2016-2027)
Table 46:Market Size of Von Willebrand Disease by therapies in the UK, in USD Million (2016-2027)
Table 47:Market Size of Von Willebrand Disease in Japan, in USD Million (2016-2027)

List of Figures
Figure 1: The structure of VWF
Figure 2: Biosynthesis and Function of von Willebrand Factor
Figure 3: The role of von Willebrand factor (VWF) in hemostasis.
Figure 4: Type 2 VWD Variants.
Figure 5: Pathophysiological Mechanisms and Classification of von Willebrand Disease
Figure 6: Initial hemostasis laboratory evaluation
Figure 7: Algorithm proposed for the diagnosis and classification of VWD
Figure 8: Comparison of the multimeric structure of plasma VWF from VWD patients and normal individuals.
Low (A) and intermediate (B) resolution VWF multimer analysis
Figure 9: Total Diagnosed Prevalent Patient Population of Von Willebrand Disease in the 7MM (2016-2027)
Figure 10: Diagnosed Prevalence of Von Willebrand Disease in the United States (2016-2027)
Figure 11: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2016-2027)
Figure 12: Type Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2016-2027)
Figure 13: Age Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2016-2027)
Figure 14: Total Diagnosed Prevalent Population of Von Willebrand Disease in Germany (2016-2027)
Figure 15: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2016-2027)
Figure 16: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2016-2027)
Figure 17: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2016-2027)
Figure 18: Total Diagnosed Prevalent Population of Von Willebrand Disease in France (2016-2027)
Figure 19: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in France (2016-2027)
Figure 20: Type Specific Diagnosed Prevalence of Von Willebrand Disease in France (2016-2027)
Figure 21: Age Specific Diagnosed Prevalence of Von Willebrand Disease in France (2016-2027)
Figure 22: Total Diagnosed Prevalent Population of Von Willebrand Disease in Italy (2016-2027)
Figure 23: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2016-2027)
Figure 24: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2016-2027)
Figure 25: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2016-2027)
Figure 26: Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain (2016-2027)
Figure 27: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2016-2027)
Figure 28: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2016-2027)
Figure 29: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2016-2027)
Figure 30: Total Diagnosed Prevalent Population of Von Willebrand Disease in the UK (2016-2027)
Figure 31: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2016-2027)
Figure 32: Type Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2016-2027)
Figure 33: Age Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2016-2027)
Figure 34: Total Diagnosed Prevalent Population of Von Willebrand Disease in Japan (2016-2027)
Figure 35: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2016-2027)
Figure 36: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2016-2027)
Figure 37: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2016-2027)
Figure 38: Unmet Needs of von Willebrand Disease
Figure 39: 7 Major Market Size of Von Willebrand Disease in USD Million (2016-2027)
Figure 40: Market Size of Von Willebrand Disease in the US, USD Millions (2016-2027)
Figure 41: Market size of Von Willebrand Disease by therapies in the US, in USD Million (2016-2027)
Figure 42: Market Size of Von Willebrand Disease in Germany, USD Millions (2016-2027)
Figure 43: Market Size of Von Willebrand Disease by therapies, in Germany, in USD Million (2016-2027)
Figure 44: Market Size of Von Willebrand Disease in France, USD Millions (2016-2027)
Figure 45: Market Size of Von Willebrand Disease by therapies, in France, in USD Million (2016-2027)
Figure 46: Market Size of Von Willebrand Disease in Italy, USD Millions (2016-2027)
Figure 47: Market Size of Von Willebrand Disease by therapies in Italy, in USD Million (2016-2027)
Figure 48: Market Size of Von Willebrand Disease in Spain, USD Millions (2016-2027)
Figure 49: Market Size of Von Willebrand Disease by therapies in Spain, in USD Million (2016-2027)
Figure 50: Market Size of Von Willebrand Disease in the UK, USD Millions (2016-2027)
Figure 51: Market Size of Von Willebrand Disease by therapies in the UK, in USD Million (2016-2027)
Figure 52:Market Size of Von Willebrand Disease in Japan, USD Millions (2016-2027)
Figure 53: Market Drivers
Figure 54:Market Barriers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Shire
  • CSL- Behring
  • Octa Pharma
  • LFB
  • Ferring Pharmaceuticals
  • Grifols Biological Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll